Of all patients with acute myocardial infarction (AMI), 4–7% have a culprit lesion in the left main coronary artery whose abrupt occlusion triggers ischemia and myocardial infarction (MI) [
1,
2]. Unprotected left main coronary artery occlusion–induced AMI (LM-AMI) often presents with cardiogenic shock and is associated with higher risks of major cardiac adverse events and higher mortality even if treated with reperfusion therapy in time [
3,
4]. Coronary artery bypass graft (CABG) is recognized as the standard revascularization strategy for this situation [
5,
6]. Nonetheless, although CABG is recommended by the guidelines, it still carries very high mortality in patients with LM-AMI. Percutaneous coronary intervention (PCI) for LM-AMI was revealed to have a clinical outcome comparable to that of CABG in recent studies because of the application of second-generation drug-eluting stents and improvement of PCI procedure [
7]. Primary PCI (PPCI) for LM-AMI is an alternative revascularization strategy to CABG for selected patients.
Stents are immediately implanted in conventional PPCI after successful revascularization, and 12–30% of patients underwent immediate stenting have not achieved thrombolysis in myocardial infarction (TIMI) grade 3 flow, which usually indicates impaired perfusion and unfavorable clinical outcome [
8]. Impaired perfusion or no-reflow phenomenon, partly explained by distal embolization and microvascular obstruction caused by stent implantation, may induce increased infarct area, reduced ventricular function, and poor prognosis [
9]. In addition, no-reflow–triggered ischemia reperfusion injury after immediate stenting may cause ventricular arrhythmia, myocardial stunning, and even sudden death [
10,
11]. Deferred stent implantation, as an alternative strategy, can attenuate distal embolization and reperfusion injury since enhanced anti-thrombotic therapies and myocardial preconditioning of oxidative stress can be applied during the delayed period. On the other hand, deferred stent implantation provides doctors with time to apply anti-thrombotic therapy to alleviate thrombus burden and optimize stent implantation. The efficacy of deferred stenting was supported by some studies with improved peri-procedure outcome and potential favorable long-term prognosis [
12‐
16]. In contrast, several studies, including three randomized controlled trials (RCTs), failed to prove the advantage of delayed stenting and even led to controversial conclusions [
17‐
19]. Further investigation is necessary to evaluate the safety and efficacy of deferred stent implantation for LM-AMI. Therefore, the present study is aimed to compare deferred stent implantation with conventional procedure and optimize the standard PCI procedure for patients with LM-AMI.